Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma
Clinical trial NCT05058755 · COMPLETED
Trial details
- NCT number
- NCT05058755
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- Status
- COMPLETED
- Phase
- Not Applicable
- Study type
- INTERVENTIONAL
- Start date
- 2021-09-17
- Primary completion
- 2022-12-30
- Enrollment
- 62
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.